For: | Salvadori M, Rosso G. Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects. World J Nephrol 2016; 5(1): 6-19 [PMID: 26788460 DOI: 10.5527/wjn.v5.i1.6] |
---|---|
URL: | https://www.wjgnet.com/2220-6124/full/v5/i1/6.htm |
Number | Citing Articles |
1 |
Christina Soeun Kwon, Patrick Daniele, Anna Forsythe, Christopher Ngai. A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy. Journal of Health Economics and Outcomes Research 2021; 8(2): 36 doi: 10.36469/jheor.2021.26129
|
2 |
Christina Soeun Kwon, Patrick Daniele, Anna Forsythe, Christopher Ngai. A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy. Journal of Health Economics and Outcomes Research 2021; 8(2) doi: 10.36469/001c.26129
|
3 |
Magdalena Krochmal, Katryna Cisek, Szymon Filip, Katerina Markoska, Clare Orange, Jerome Zoidakis, Chara Gakiopoulou, Goce Spasovski, Harald Mischak, Christian Delles, Antonia Vlahou, Joachim Jankowski. Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-09393-w
|
4 |
Ling-Wei Jin, Han-Yang Ye, Xiao-Yan Xu, Yu Zheng, Yan Chen. MiR-133a/133b inhibits Treg differentiation in IgA nephropathy through targeting FOXP3. Biomedicine & Pharmacotherapy 2018; 101: 195 doi: 10.1016/j.biopha.2018.02.022
|